CN204600534U - Collect the tissue cage model of beasle dog subcutaneous tissue liquid - Google Patents
Collect the tissue cage model of beasle dog subcutaneous tissue liquid Download PDFInfo
- Publication number
- CN204600534U CN204600534U CN201520300412.7U CN201520300412U CN204600534U CN 204600534 U CN204600534 U CN 204600534U CN 201520300412 U CN201520300412 U CN 201520300412U CN 204600534 U CN204600534 U CN 204600534U
- Authority
- CN
- China
- Prior art keywords
- tissue
- cage model
- model
- silicone tube
- cage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001519 tissue Anatomy 0.000 title claims abstract description 79
- 239000007788 liquid Substances 0.000 title claims abstract description 16
- 206010033675 panniculitis Diseases 0.000 title claims abstract description 12
- 210000004304 subcutaneous tissue Anatomy 0.000 title claims abstract description 12
- 239000012530 fluid Substances 0.000 claims abstract description 21
- 229920002529 medical grade silicone Polymers 0.000 claims abstract description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000741 silica gel Substances 0.000 claims abstract description 13
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 13
- 229960001866 silicon dioxide Drugs 0.000 claims abstract description 13
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 23
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 210000003722 extracellular fluid Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001561899 Otomys Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Prostheses (AREA)
Abstract
This utility model relates to a kind of tissue cage model collecting beasle dog subcutaneous tissue liquid, select medical silicone tube as the main body of this tissue cage model, respectively offer at least 4 equally distributed tissue fluids at the two ends of medical silicone tube and exchange aperture, the diameter that this tissue fluid exchanges aperture is 2mm, the two-port of medical silicone tube is by medical silica-gel disk seal closure, the outside dimension of this tissue cage model is 16.0 ~ 20.0mm, internal diameter size is 11.0 ~ 15.0mm, tissue cage model length is 63 ~ 67mm, and volume is about 6.0 ~ 11.0cm
3.Use disposable syringe to thrust extracting interstitial fluid in tissue cage in vitro, the related direction researchs such as medicine in-vivo tissue liquid pharmacokinetics, pharmacodynamics, antibiotic antibacterial activity in vivo and drug resistance can be carried out.
Description
Technical field
This utility model relates to drug test research field, particularly relates to a kind of tissue cage model collecting animal skins undertissue liquid.
Background technology
Entered the medicine in body by different modes of administration, first arriving blood by absorbing, being then transported to each target organ of body, target tissue again.What tradition pharmacokinetic studies detected is the drug level of blood plasma or serum.And there is different infiltration ratios in blood plasma and organ-tissue, blood plasma or drug in blood serum concentration can not represent in reality completely organizes drug concentration.And another large body fluid of body, tissue fluid be but pathogenic microorganism or its toxin infringement parenchyma must through place, equally also be the ground at various kinds of drug treatment damaged tissues or cell and the place playing drug effect.Thus, we are when carrying out pharmaceutical research to medicine, and it is of equal importance that blood and tissue fluid Chinese medicine move pharmacodynamics, and tissue fluid drug concentration more can actual response target site drug level and therapeutic effect.Tissue fluid is not identical with blood constituent, medicine enters tissue fluid by various factors such as the chemical constitution of medicine own, ionization property, permeability, protein binding rates by blood, thus there is larger gap in tissue or tissue fluid drug concentration and blood drug concentration, and characteristics of pharmacokinetics is also and incomplete same in these two kinds of body fluid for medicine.So it is not only move one of pharmacodynamic study as blood Chinese medicine to supplement effectively that drug entities liquid Chinese medicine moves pharmacodynamic study, but when thoroughly evaluating pharmacopathology feature an indispensable part.
What is more important, for antibiotic medicine research, uses tissue cage model, by injecting antibacterial in tissue cage, can carry out medicine in complete body dynamic-pharmacodynamics and the research of medicine Catastrophic selection window.Now, pathogen, antibacterials be same fixed-site interaction in animal body, closer to real treatment situation.In recent years, different genera animal (cattle, sheep, goat, rabbit, cat, etc.) tissue fluid pharmacokinetics and efficacy has relevant report.This mainly gives the credit to and the successful foundation of tissue cage model at different animals, this type of test is carried out between different target animals, systematic study medicine at different genera animal pharmacology characteristic and drug resistance, for medication reasonable in design provides accurate guidance.
Due to different animals physiological property, particularly epithelial properties is different, and the tissue cage model thus implanted in animal skins undertissue is not identical yet.At present, the tissue cage be applicable in the animal body such as cattle, rabbit has commodity selling, i.e. golf model.But this model volume is comparatively large, and be not suitable for skin comparatively closely with it beasle dog.Therefore, need to invent a kind of novel tissue cage model, for beasle dog in-vivo tissue liquid correlational study.
Summary of the invention
The object of the present invention is to provide a kind of tissue cage model being applicable to beasle dog in-vivo tissue liquid correlational study, this model, by after manual manufacture molding, is implanted beasle dog subcutaneous tissue, can be collected limpid yellow tissue fluid after one period of convalescent period.
The object of the invention is to be achieved through the following technical solutions:
A kind of tissue cage model collecting beasle dog subcutaneous tissue liquid, select medical silicone tube as the main body of this tissue cage model, respectively offer at least 4 equally distributed tissue fluids at the two ends of medical silicone tube and exchange aperture, the diameter that this tissue fluid exchanges aperture is 2mm, the two-port of medical silicone tube is by medical silica-gel disk seal closure, the outside dimension of this tissue cage model is 16.0 ~ 20.0 mm, internal diameter size is 11.0 ~ 15.0 mm, tissue cage model length is 63 ~ 67mm, and volume is about 6.0 ~ 11.0cm
3.
The outside dimension of this tissue cage model is 18.0 mm, and internal diameter size is 13.0 mm, and tissue cage model length is 65 mm, and volume is 8.0 cm
3.
The two ends of this tissue cage model respectively offer equally distributed 8 tissue fluids and exchange aperture, and it is 50 ~ 50.5 mm that tissue fluid exchanges total surface area
2.
Described medical silica-gel disk first uses nylon line suture in the two-port of medical silicone tube, then uses 705 silica gel bondings to close gap.
The beneficial effects of the utility model are:
1, described tissue cage model, selected material is medical silicone tube, has good biocompatibility, and low price, convenient acquisition;
2, described tissue cage model, manufacturing process is simple, and make by hand for pure, applicable laboratory is promoted the use of;
3, by control experiment, determine best making dog tissue cage used silica gel pipe internal-and external diameter specification, better instruct the making of dog tissue cage model;
4, described tissue cage model, after surgically implanting beasle dog subcutaneous tissue, clear yellow tissue fluid can be collected after 4-5 week, be applicable to beasle dog in-vivo tissue liquid correlational study completely, and do not have any tissue cage model to reach this requirement in the market.
Accompanying drawing explanation
Fig. 1 is tissue cage schematic diagram in kind;
Fig. 2 is silica gel disk schematic diagram.
Wherein: 1, medical silicone tube, 2, the two ends of medical silicone tube, 3, exchange aperture, 4, medical silica-gel disk.
Detailed description of the invention
This utility model is further described below by embodiment.
Embodiment 1
The main body of this tissue cage model selects medical silicone tube (1), and biocompatibility is better.Tissue cage model specification is: external diameter 18.0 mm, internal diameter 13.0 mm, and being about is 65 ± 2 mm, and volume is about 8.0 cm
3; Each at the two ends (2) of medical silicone tube to make a call to 8 diameters be 2.0 mm apertures, makes tissue cage and environmental liquids exchange area be 50.3 mm
2.Medical silica-gel disk (4) first uses nylon line suture in the two ends (2) of medical silicone tube, then uses 705 silica gel bondings to close gap.
After the tissue cage completed cleans up, to spend the night soaking disinfection with bromogeramine solution, for subsequent use after drying.After first beasle dog anaesthetizes sb. generally with pentobarbital sodium, hair is shaved at back, both sides, iodine tincture disinfection and ethanol take off iodine, with procaine hydrochloride, local anesthesia is carried out to art, with scalpel otomy portion skin under aseptic condition, with tweezers and operating scissors, blunt separation is carried out to wound again, the wound size degree of depth is suitable fills in subcutaneous tissue afterwards tissue cage, finally use suture wound, and on sew up wound, coat tetracycline ointment in case wound infection, intragluteal injection penicillin sodium injection, carries out whole body anti-inflammation.Through intensive care in 1 week, wound healing, removed stitching thread after 10 days.Tissue cage outer wrapping one deck connective tissue after 4-5 week, tissue fluid enters tissue cage collect by being positioned at tissue cage two ends aperture.Outside skin, thrust sucking-off clear yellow tissue fluid in tissue cage with Dispoable medical syringe, illustrate that tissue cage model is successfully set up, can correlation test be carried out.
Embodiment 2
Best silica gel tube specification is determined by control experiment:
Select the medical silicone tube of different size, make tissue cage model according to embodiment 1, and be implanted into dog subcutaneous tissue of back, continuous observation 1-2 month, and collection organization's liquid, assessment tissue cage model success rate, thus select the optimum medical silicone tube size of making organize models.Result is as following table:
Claims (4)
1. collect the tissue cage model of beasle dog subcutaneous tissue liquid for one kind, it is characterized in that the main body selecting medical silicone tube as this tissue cage model, respectively offer at least 4 equally distributed tissue fluids at the two ends of medical silicone tube and exchange aperture, the diameter that this tissue fluid exchanges aperture is 2mm, the two-port of medical silicone tube is by medical silica-gel disk seal closure, the outside dimension of this tissue cage model is 16.0 ~ 20.0 mm, internal diameter size is 11.0 ~ 15.0 mm, tissue cage model length is 63 ~ 67mm, and volume is about 6.0 ~ 11.0cm
3.
2. the tissue cage model of collection beasle dog subcutaneous tissue liquid according to claim 1, it is characterized in that the outside dimension of this tissue cage model is 18.0 mm, internal diameter size is 13.0 mm, and tissue cage model length is 65 mm, and volume is 8.0 cm
3.
3. the tissue cage model of collection beasle dog subcutaneous tissue liquid according to claim 1, it is characterized in that the two ends of this tissue cage model respectively offer equally distributed 8 tissue fluids and exchange aperture, it is 50 ~ 50.5 mm that tissue fluid exchanges total surface area
2.
4. the tissue cage model of collection beasle dog subcutaneous tissue liquid according to claim 1, is characterized in that described medical silica-gel disk first uses nylon line suture in the two-port of medical silicone tube, then uses 705 silica gel bondings to close gap.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520300412.7U CN204600534U (en) | 2015-05-12 | 2015-05-12 | Collect the tissue cage model of beasle dog subcutaneous tissue liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520300412.7U CN204600534U (en) | 2015-05-12 | 2015-05-12 | Collect the tissue cage model of beasle dog subcutaneous tissue liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204600534U true CN204600534U (en) | 2015-09-02 |
Family
ID=53953135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520300412.7U Expired - Fee Related CN204600534U (en) | 2015-05-12 | 2015-05-12 | Collect the tissue cage model of beasle dog subcutaneous tissue liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204600534U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104799885A (en) * | 2015-05-12 | 2015-07-29 | 苏州圣苏新药开发有限公司 | Tissue cage model for collecting subcutaneous tissue fluid of beagle and using method |
-
2015
- 2015-05-12 CN CN201520300412.7U patent/CN204600534U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104799885A (en) * | 2015-05-12 | 2015-07-29 | 苏州圣苏新药开发有限公司 | Tissue cage model for collecting subcutaneous tissue fluid of beagle and using method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103828763B (en) | A kind of liver cancer patient source xenograft tumor mouse model and construction method thereof | |
| Dogangil et al. | Toward targeted retinal drug delivery with wireless magnetic microrobots | |
| Serwer et al. | Systemic and local drug delivery for treating diseases of the central nervous system in rodent models | |
| CN105031609B (en) | The disinfectant and its preparation and use of the Cbf-14 containing antibacterial peptide | |
| Papich et al. | Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs | |
| Tu et al. | Evaluation of biomaterials for bladder augmentation using cystometric analyses in various rodent models | |
| CN103736080A (en) | Preparation used for healing wound, preparation method and application thereof | |
| CN204600534U (en) | Collect the tissue cage model of beasle dog subcutaneous tissue liquid | |
| Higgins et al. | Development of equine models ofinflammation | |
| Foditsch et al. | Cystometric and external urethral sphincter measurements in awake rats with implanted catheter and electrodes allowing for repeated measurements | |
| CN107836409A (en) | A kind of construction method of breast cancer orthotopic PDX models | |
| CN104799885A (en) | Tissue cage model for collecting subcutaneous tissue fluid of beagle and using method | |
| CN206675805U (en) | A kind of antibacterial temperature measuring type catheter | |
| CN103479680A (en) | Method and kit for establishing experimental model of diabetic foot ulcer big mouse infected by staphylococcus aureus | |
| CN110278919A (en) | A method of building vermiform mite causes acne rosacea sample skin lesion animal model | |
| CN107334491B (en) | In vivo enrichment device for circulating free DNA | |
| Simeonova et al. | Assessment of surgical sutures Polymed by intracutaneous irritation test in rabbits | |
| CN104127258A (en) | Mouse uterus perfusion apparatus and method for establishing mouse endometritis model | |
| Clarke et al. | Subcutaneously implanted tissue chambers: a pathophysiological study | |
| RU2714949C2 (en) | Method for simulating local circumscribed peritonitis in rats | |
| CN113244011A (en) | Construction method and medical application of brain metastasis cancer animal model | |
| Jurek et al. | Effect of perfusate volume on amikacin concentrations after saphenous intravenous regional limb perfusion in standing, sedated horses | |
| Sammeta et al. | Dermal drug levels of antibiotic (cephalexin) determined by electroporation and transcutaneous sampling (ETS) technique | |
| CN204411021U (en) | A kind of animal mamma as raw material injection needle apparatus | |
| CN109513092A (en) | Intubation conduit, administered by infusion device and animal test model in zoopery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 |